Harsh Shah 7/22/26 Harsh Shah 7/22/26

Why drugs fail FDA review on quality, not science

FDA released 202 Complete Response Letters in July 2025. Manufacturing and quality deficiencies appeared in 74% of them. The clinical data was rarely the problem.

Harsh Shah 7/2/26 Harsh Shah 7/2/26

Deviation investigation cost and CAPA closure benchmarks: what the numbers actually say

Same 21 CFR rules at four people as at forty. A clinical-stage biotech carries enterprise regulatory requirements on startup resources, which is why the ROI math for AI in QMS looks nothing like the enterprise pharma case.

Harsh Shah 6/1/26 Harsh Shah 6/1/26

Benefits of Integrating AI into Quality Management Systems for Biotech Firms

Same 21 CFR rules at four people as at forty. A clinical-stage biotech carries enterprise regulatory requirements on startup resources, which is why the ROI math for AI in QMS looks nothing like the enterprise pharma case.

Harsh Shah 6/1/26 Harsh Shah 6/1/26

Tools That Detect Systemic Compliance Issues in Pharmaceutical Manufacturing

A systemic compliance issue lives in the relationships between records, not in any single one. Most tools process records one at a time, which is structurally the wrong shape to catch the pattern an inspector eventually does.

Harsh Shah 6/1/26 Harsh Shah 6/1/26

Real-Time Analysis of Quality Records Against Regulatory Standards: The Five Platform Categories

The platforms that touch your quality records mostly store them. Real-time content evaluation against the regulation is a different category of product, and confusing the two is how QMS evaluations end in misaligned procurement.

Harsh Shah 4/28/26 Harsh Shah 4/28/26

Real-Time Analysis of Quality Records: Comparing the Five Platforms Pharma and Biotech Evaluate

Five platforms come up in pharma and biotech evaluations for real-time quality record analysis. Four are systems of record. One is an intelligence layer. Understanding the difference is what separates a useful evaluation from a confused one.

Harsh Shah 4/28/26 Harsh Shah 4/28/26

7 Benefits of Integrating AI into Quality Management Systems for Biotech Firms

Biotech firms run identical regulatory frameworks to large pharma with a fraction of the QA headcount. AI in QMS closes that gap without replacing Veeva, MasterControl, or TrackWise. Here are the seven measurable benefits and how integration actually works.

Harsh Shah 4/10/26 Harsh Shah 4/10/26

Proactively Identify FDA Inspection Risks with AI

FDA inspections do not create compliance failures. They surface ones that already existed. AI regulatory intelligence replaces point-in-time mock audits with continuous gap detection across 150+ frameworks — FDA 21 CFR, EU GMP, and ICH — from preclinical through post-market surveillance. Here's how the four-pillar platform closes the loop before inspectors arrive.

Harsh Shah 2/12/26 Harsh Shah 2/12/26

Complete Guide to Drug Lifecycle Regulatory Compliance

Every pharmaceutical product moves through a regulated lifecycle — from the first preclinical study to post-market surveillance. This guide maps the complete regulatory landscape across all five domains: GLP, GCP, GMP, eCTD submissions, and pharmacovigilance. Frameworks, documentation requirements, and where compliance gaps most commonly occur.

Harsh Shah 2/12/26 Harsh Shah 2/12/26

AI-Powered Submission Readiness: How Regulatory Intelligence Prevents Complete Response Letters — Clinplex AI

Complete Response Letters trace to documentation deficiencies that existed months before filing. AI-powered submission readiness scoring evaluates eCTD Modules 1–5 against ICH M4 content requirements, verifies cross-module consistency, and quantifies NDA/BLA readiness — identifying gaps that trigger CRLs before the submission is filed.

Harsh Shah 2/12/26 Harsh Shah 2/12/26

How AI Is Transforming GCP Compliance and Clinical Trial Regulatory Intelligence

Clinical trial compliance generates thousands of regulatory documents across sites and jurisdictions. AI regulatory intelligence evaluates every clinical document against ICH E6(R2), 21 CFR 312, and FDA guidance — continuously, not just during periodic GCP audits. Cross-domain connections link clinical findings to manufacturing, submission, and pharmacovigilance implications.